Actively Recruiting
Phase I Study of GT101 Injection as Treatment for Adults with Metastatic or Recurrent Solid Tumors
Led by Grit Biotechnology · Updated on 2026-09-14
31
Participants Needed
5
Research Sites
65 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a multicenter, single-arm phase I clinical trial to evaluate an autologous tumor-infiltrating lymphocyte therapy called GT101 for adults with metastatic or recurrent solid tumors. The study aims to assess the safety and treatment effects of this approach, which involves a series of treatment steps including lymphodepleting chemotherapy and immune therapy infusion. Participants receive a lymphodepleting chemotherapy regimen consisting of cyclophosphamide and fludarabine, followed by an infusion of GT101, which is a biological treatment made from the patients own tumor-infiltrating lymphocytes. After the infusion, participants receive intravenous interleukin-2 to support the immune response. The study includes distinct periods for screening, tissue sampling and therapy preparation, chemotherapy, treatment and observation, and follow-up. During the trial, participants will be closely monitored through various assessments including safety evaluations of treatment-related adverse events, tumor response rates, overall survival, progression-free survival, disease control rate, and duration of response over a three-year period. The full participation period includes these stages and follow-up visits, ensuring thorough observation of treatment effects and safety over time.
CONDITIONS
Brief Title
GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors
Research Team
H
Haifeng Qin, PhD
Y
Yongsheng Wang, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here